Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: awaiting (67), pending (44)

Carboplatin(AUC2)-Paclitaxel (7 day)

Description: A chemotherapy protocol on Carboplatin (AUC2) Paclitaxel.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CarboplatinAUC2-Paclitaxel7day.pdf

Cisplatin-Etoposide (intravenous and oral)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CISPLATIN-ETOPOSIDE (Intravenous / Oral) Regimen SCLC – Cisplatin-Etoposide IV/PO Indication Limi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Cisplatin-Etoposideintravenousandoral.pdf

Squint surgery for adults - patient information

Description: We have given you this factsheet because you are on the waiting list for an operation to correct your squint.
Url: /Media/UHS-website-2019/Patientinformation/Eyes/Squint-surgery-for-adults-1780-PIL.pdf

Cisplatin-Etoposide (intravenous)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CISPLATIN-ETOPOSIDE (Intravenous) Regimen SCLC – Cisplatin-Etoposide IV Indication Limited stage
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Cisplatin-Etoposideintravenous.pdf

Paclitaxel (7 day)

Description: Chemotherapy Protocol BLADDER CANCER PACLITAXEL (7 day) Regimen • Bladder Cancer – Paclitaxel (7 day) Indication •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Paclitaxel-7-day.pdf

Osimertinib

Description: Chemotherapy Protocol Lung cancer - Non-small cell (NSCLC) OSIMERTINIB Regimen • NSCLC - Osimertinib Indication • Osimertinib is available as an
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Osimertinib.pdf

REPOCH (dose adjusted)-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine

Description: Chemotherapy Protocol LYMPHOMA REPOCH - CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONERITUXIMAB-VINCRISTINE (Dose adjusted
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/REPOCH-dose-adjusted-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine.pdf

Bexarotene

Description: Chemotherapy Protocol Cutaneous T-cell Lymphoma BEXAROTENE Regimen • Cutaneous T-cell Lymphoma - Bexarotene Indication • Bexarotene is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bexarotene.pdf

Bendamustine-Polatuzumab-Rituximab

Description: Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-POLATUZUMAB-RITUXIMAB Regimen • Lymphoma – Bendamustine-Polatuzumab-Rituximab Indication • Histolog
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Polatuzumab-Rituximab.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description: Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma –
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf

391 to 400 of 1000

Previous … 38 39 40 41 42 … Next